Could the hybrid business model cope with difficult conditions in the capital markets?
” AH: “In today’s market, the availability of capital to biotech companies is worse than ever. In this climate, biotech companies need to find ways to keep their financial burn at a minimum. A hybrid business model with a cash-generating segment can provide that, and may prove to be especially beneficial under the current conditions.
